Synonym
CGS 22652; CGS22652; CGS-22652
IUPAC/Chemical Name
3-Pyridineheptanoic acid, gamma-(4-(((4-chlorophenyl)sulfonyl)amino)butyl)-, (+-)-
InChi Key
ISMHAZMNDUAHLK-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H29ClN2O4S/c23-20-10-12-21(13-11-20)30(28,29)25-16-2-1-5-18(9-14-22(26)27)6-3-7-19-8-4-15-24-17-19/h4,8,10-13,15,17-18,25H,1-3,5-7,9,14,16H2,(H,26,27)
SMILES Code
O=C(O)CCC(CCCCNS(=O)(C1=CC=C(Cl)C=C1)=O)CCCC2=CC=CN=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
452.99
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Boussairi EH, Sacquet J, Benzoni D, Sassard J. Blood pressure effects of thromboxane A2 blockade in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993 Nov;20(11):679-87. doi: 10.1111/j.1440-1681.1993.tb01652.x. PMID: 8306513.
2: Olson RW, Dotson R, Mathis J, Cohen DS, Webb RL. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis. Eur J Pharmacol. 1993 May 12;236(1):75-87. doi: 10.1016/0014-2999(93)90229-b. PMID: 8319746.
3: Zhu Y, Park TS, Gidday JM. Mechanisms of hyperoxia-induced reductions in retinal blood flow in newborn pig. Exp Eye Res. 1998 Sep;67(3):357-69. doi: 10.1006/exer.1998.0535. PMID: 9778417.
4: Stelling MS, Maniara WM, Powell ML. A quantitative analytical method for the determination of a new thromboxane synthetase inhibitor (CGS 22652) in human plasma using high performance liquid chromatography. Biomed Chromatogr. 1994 Sep-Oct;8(5):247-50. doi: 10.1002/bmc.1130080510. PMID: 7841770.
5: Li Z, Su X, Chapleau MW. Role of cyclooxygenase metabolites in mediating platelet-induced baroreceptor dysfunction. Am J Physiol. 1995 Aug;269(2 Pt 2):H599-608. doi: 10.1152/ajpheart.1995.269.2.H599. PMID: 7653624.
6: Beauchamp MH, Martinez-Bermudez AK, Gobeil F Jr, Marrache AM, Hou X, Speranza G, Abran D, Quiniou C, Lachapelle P, Roberts J 2nd, Almazan G, Varma DR, Chemtob S. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J Appl Physiol (1985). 2001 Jun;90(6):2279-88. doi: 10.1152/jappl.2001.90.6.2279. PMID: 11356793.
7: Boussairi EH, Sacquet J, Sassard J, Benzoni D. Thromboxane A2-prostaglandin H2 and renovascular hypertension in rats. Am J Physiol. 1994 Nov;267(5 Pt 2):R1190-7. doi: 10.1152/ajpregu.1994.267.5.R1190. PMID: 7977845.
8: Bhagwat SS, Gude C, Cohen DS, Dotson R, Mathis J, Lee W, Furness P. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid. J Med Chem. 1993 Jan 22;36(2):205-10. doi: 10.1021/jm00054a003. PMID: 8423593.
9: Bhagwat SS, Gude C, Boswell C, Contardo N, Cohen DS, Dotson R, Mathis J, Lee W, Furness P, Zoganas H. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs. J Med Chem. 1992 Nov 13;35(23):4373-83. doi: 10.1021/jm00101a015. PMID: 1447738.
